Local Recurrence and Distant Metastases after Breast Conservation Treatment in Women with Triple Negative Breast Cancer Subtype
|
|
- Emerald Bryant
- 5 years ago
- Views:
Transcription
1 Local Recurrence and Distant Metastases after Breast Conservation Treatment in Women with Triple Negative Breast Cancer Subtype Amr Ghannam 1, Omnia Abd el-fattah 1 and Ayman El-Nemr 2 1 Clinical Oncology and 2 Surgical Oncology Departments, Faculty of Medicine, Tanta University omniaabdelfattah@yahoo.com Abstract: Introduction: Recently, gene expression studies using DNA microarrays have identified five common subtypes of breast cancer. The triple negative (TN) phenotype, which includes tumors that do not express ER, PR, or HER2 serves as a proxy for the basal-like subtype. At the present time, there is little clinical data evaluating whether a particular breast cancer subtype is associated with increased rates of local and/or distant recurrence after BCT.Objective: to evaluate the outcome after breast conservation therapy for triple-negative early-stage invasive breast carcinoma. Materials and methods: Between 2000 and 2010, 421 patients with early stage breast cancer patients who treated with BCT were classified as TN (58) if they were negative for all three receptors (ER, PR, and HER2/neu) or as non TN (363) if they were positive for any of the three markers. These patients were evaluated for isolated local and distant recurrence. Results: The local relapse rates among the TN group were nearly equal to those of the non TN. (5.2% vs. 3.9% P= 0.63) five-years overall and disease free survival of the TN group were significantly poorer than the other group( 62% vs 85 % p=0.002 ) and (39 % vs 75% p= 0.00 ). The isolated local relapse free survival was 90.3% vs 95.7% between the 2 groups. (P= 0.365) while the isolated distant metastases free survival was 52% vs 84%. (P= 0.00). Conclusions: Although women with TN tumors had a higher rate of local failure and a lower rate of freedom from distant metastases compared with women without TN tumors, the absolute difference was relatively small and is not statistically significant and therefore does not preclude BCT for women with TN early-stage invasive breast carcinoma. [Amr Ghannam, Omnia Abd el-fattah and Ayman El-Nemr. Local Recurrence and Distant Metastases after Breast Conservation Treatment in Women with Triple Negative Breast Cancer Subtype. Life Sci J 2012;9(3): ]. (ISSN: ).. 26 Keywords: Breast Cancer, Hormone Receptor Negative, HER-2/neu Local recurrence. 1. Introduction Breast cancer encompasses a heterogeneous population of tumors characterized by a variety of clinical, pathological, and molecular features [1-3]. Molecular markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) have been used to classify patients into different subtypes. Recently, gene expression studies using DNA microarrays have identified five common subtypes of breast cancer: luminal A (ER or PR positive and HER2 negative), luminal B (ER or PR positive and HER2 positive), HER2 overexpressing (ER and PR negative and HER2 positive), basal-like (ER, PR, and HER2 negative, CK 5/6 positive) and normal breast-like tumor [2,4-6]. HER2 overexpressing and basal-like subtypes are significantly more likely to be grade 3 and are associated with worse recurrence rates and decreased overall survival [3,5-7]. The triple negative (TN) phenotype, which includes tumors that do not express ER, PR, or HER2 on immunohistochemistry (IHC), serves as a proxy for the basal-like subtype with a positive predictive value of approximately 80-97% [8,9]. Although this approach is not complete, several groups have adopted a TN definition for basal-like cancer out of convenience. Several randomized trials have demonstrated molecular markers were available. The data on ER, PR, and HER2/neu were obtained through standard clinical testing, using immunohistochemistry for ER and PR and the HER2/neu. For ER and PR, receptor positivity was based on more than 10% of cells testing positive. HER2/neu scores of 0 and 1 were considered negative, and Positive HER2 was determined using either IHC 3+ staining or amplification on fluorescence in situ hybridization (FISH) in patients with IHC 2+. Patients were classified as triple negative if they were negative for all three receptors or as non triple negative if they were positive for any of the three markers. Exclusion criteria for this study included male breast cancer, T3 disease, mastectomy, previous or concurrent malignancy (breast or other site)or patients treated without radiotherapy. All patients were treated with breast-conserving surgery followed by radiation therapy. The surgical treatment included complete gross excision of the primary tumor. Re-excision of the primary tumor was done if possible if positive margin was proved. Pathologic axillary lymph node staging was performed for all patients. Earlier in the study period, pathologic axillary lymph node staging was generally performed 175
2 using a lower axillary lymph node that survival rates following breast-conserving treatment (BCT) were equivalent to those observed with radical mastectomy [10-12]. Given these results, BCT has become an accepted treatment for early stage breast cancer [13]. At the present time, there is little clinical data evaluating whether a particular breast cancer subtype is associated with increased rates of local and/or distant recurrence after BCT [14-17]. The outcome after breast conservation treatment with radiation has not been well described for triplenegative early-stage invasive breast carcinoma. Therefore, the current study was performed to evaluate the outcome after breast conservation treatment with radiation for this subtype of breast carcinoma. 2. Materials and Methods Between the year 2000 and 2010, 759 patients with American Joint Committee on Cancer stages I-II (18) disease were treated with breast-conserving surgery followed by radiation therapy to the intact breast, with or without systemic therapy, at the Clinical Radiation Oncology Department, Tanta University hospital. Only those patients in whom ER, PR, and HER2/neu status were available were included in the current analysis. This limited the sample to a total of 421 patients in whom all three was defined as clinical evidence of distant disease based on clinical and/or radiographic findings. All events were calculated from the time of surgery to the time of the event. For the calculation of overall survival (OS), a death due to any cause was scored as a failure. For the calculation of freedom from distant metastases, a failure was scored at the time of first evidence of distant metastatic disease. The Kaplan-Meier method was used to calculate OS, freedom from distant metastases, local failure, and distant failure (19). The time period was defined as the time of surgery of breast carcinoma. The logrank test was used for statistical comparisons between groups (20) Multivariate analysis was performed using the Cox proportional hazards model (21). Chi - square test was used to compare the characteristics of patients between the 2 groups. All statistical methods was done using SPSS statistical package version Results In our series, 421 patients were classified according to ER, PR, and HER2 into either TN (58) or non TN (363) patients. TN patients represent about 14 % of the whole study group. Patients, tumor, and treatment characteristics of each group are detailed in table(1). there is a highly significant difference between both groups regarding age with about 45% of triple negative patients less than 40 years compared to 33% of non triple negative patients. The median age for patients with TN breast carcinoma was 41 years while the median age for patients without a triple negative breast carcinoma was 47 years. There was no significant difference between patients by T-size, LN status, grade, extensive intraductal component, tumor necrosis, lymphovascular invasion or resection margin. All triple negative patients received chemotherapy compared to 83% of patients in the other group. The most common regimens used were either CMF or FAC or FAC and taxanes. All eligible patients underwent BCS and post operative whole breast irradiation. For the radiation treatment to the whole breast, the median dose was 46 Gy (mean, Gy; range, Gy). The median total dose was 61 Gy (mean, Gy; range, Gy). Among non triple negative groups, 80,7% of patients received hormone therapy. Few patients with HER 2 overexpression received adjuvant trastuzumab therapy. During the follow up period, there were 3 (5.2%) and 14 (3.9%) patients in TN and non TN groups respectively who experienced isolated local in breast relapse as the first site of recurrence. the difference was non significant(p= 0.63 ). Isolated distant relapse was observed in 19(32.8 %) and 47(12.9 %) patients in TN and non TN groups respectively(p= 0.00 ). The 5-years OS and DFS rates of all patients were 82% and 71% respect. Groups respectively (P= 0.00) By multivariate Cox proportional hazard models, lymph node status, intraductal component, and use of adjuvant systemic treatment were significant prognostic factors affecting OS. Age, tumor size, lymph node status and use of systemic treatment significantly affected DFS (Table2) 4. Discussion There has been much attention focused on TNBCs since the first identification of basal-like cancers using microarray expression profiling studies in 2005 (22). There is a significant overlap between TNBCs, which are defined by immunohistochemistry, and basaloid like tumors, which are identified from gene expression profiling, such that those two entities are frequently considered synonymous from a clinical perspective.(23-24) 176
3 Table (1): Patients characteristics. AGE Tumor size L.N. GRADE EIC Necrosis Triple negative N=58 Receptors Non -triple negative N=363 Total Chi-square N % N % N % X 2 P-value <40 y >40 y T T N N N G G G Positive Negative unknown yes no unknown yes LVI RM Systemic treatment Isolated local recurrence Isolated distant recurrence no unknown negative positive close Chemotherapy alone Hormonal alone both present absent present absent Table (2): Cox proportional hazards multivariate model for overall (OS) and disease-free survival (DFS) Variable OS DFS HR 95% CI p-value HR 95% CI p-value AGE TSIZE LN grade EIC necrosis LVI Tumor subtype Systemic treatment
4 178
5 Figure 1. Cumulative incidence of local recurrence as the first event TNBCs have a poor prognosis and do not respond to therapy directed at known breast cancer growth factor targets, including hormonal therapy and trastuzumab. TNBCs are fast-growing tumors, usually have a high histologic grade, and tend to metastasize earlier compared with breast cancers that express hormone receptors (16,25). The predominant sites of metastases for TNBCs differ from the luminal subtype. They are more frequently node negative and spread, in70%of patients, to the lung and brain, whereas luminal cancers tend to metastasize, in 70% of patients, to the bone and liver. (16,22.) TNBC tumors seem to be more sensitive to chemotherapy, and although there is a sharp decrease in survival early after diagnosis, survival plateaus after 8 to 10 years (16). In the current study, we evaluated 421 patients with conservatively treated breast cancer in whom all three markers were available to validate the prognostic utility of this classification scheme and to determine whether triple negative breast cancers have a more aggressive locoregional and distant relapse rate. Among all patients included, the triple negative cohort still had a poorer prognosis than the non triple negative cohort, but the two cohorts had a similar local relapse-free survival ( 90.3 vs 95.7 in TN and non TN groups respectively, P= 0.365). In fact, the local relapse rates among the triple negative cohort were nearly equal to those of the non triple negative cohort (5.2% and 3.9% of patients in TN and non TN groups P= 0.63 ). This is of particular importance given the fact that triple negative patients are significantly younger, and younger women have been shown to have a higher rate of local relapse compared with older women(26-31), therefore, those patients should not be 179 considered poor candidates for breast-conserving therapy. The fact that these women with triple negative tumors had similar local relapse rates indicates that these tumors are not radiation resistant. This is consistent with the fact that these basal-like tumors are theoretically responsive to DNA-damaging agents and should, therefore, be relatively radiation sensitive. Larger patient cohorts with a longer follow-up will be required to further validate these data. Only limited data are available for local control after breast conservation treatment with radiation relative to biologic subtype. Haffty et al reported that there was no significant difference in local failure at 5 years for the triplenegative subgroup versus the non triple-negative subgroup (17% vs. 17%, respectively; P =.82) (14). Nguyen et al., reported the outcome for patients grouped according to ER status, PgR status, and HER2 status as a surrogate for biologic subtype of disease (15). The 5-year rate of local recurrence was 7.1% for the basal-like (triple-negative) subgroup, 8.4% for the HER2 subgroup, 1.5% for the luminal B subgroup, and 0.8% for the luminal A subgroup. In comparison with the luminal A subgroup, there was an increased rate of local failure for the basal-like (triple-negative) subgroup (P =.0099) and the HER2 subgroup (P =.012). In a study evaluating HER2 as a single factor, Harris et al., reported no difference in local failure at 5 years for the HER2-positive group compared with the HER2-negativegroup (0% vs. 2%, respectively; P =.15) (32). Parikh et al., reported an increased rate of local recurrence for premenopausal patients with CK19- negative tumors compared with CK19-positive tumors (relative risk, 3.54; P <.01) (33). For 3038 patients treated with either breast conservation treatment or mastectomy, Cheang et al., used a panel of tumor markers to define biologic subtype of disease (34). The 10-year rate of local relapse was 7% for the luminal A subgroup, 11% for the luminal B subgroup, 15% for the luminal/her2- positive subgroup, 15% for the basal-like subgroup, and 18% for the HER2-positive subgroup. For 1601 patients treated with either mastectomy or breast conservation, Dent et al., reported no significant difference in local failure for the triple-negative group compared with the non triple-negative group (HR, 0.8; P =.38) (16). There are emerging data for using genomic factors to predict the risk of local recurrence after breast conservation treatment. Using a 21-gene recurrence score assay, Mamounas et al evaluated the risk of local-regional recurrence for patients treated in the National Surgical Adjuvant Breast and Bowel Project B-14 and B-20 trials for patients with nodenegative, ER-positive breast cancer (35). After breast
6 conservation treatment with radiation for 390 patients, there was a strong interaction of localregional failure with age. For patients aged < 50 years, the 10-year rate of local-regional failure was 12.5% for tumors with a low-risk recurrence score, 27.7% for tumors with an intermediate-risk recurrence score, and 26.5% for tumors with a highrisk recurrence score (P =.057). However, the 10- year rates of local-regional recurrence were relatively low for patients aged 50 years, regardless of the results of the recurrence score assay (3.6% vs. 3.7% vs. 4.8%, respectively; P =.663). Nuyten et al., reported that the wound response signature obtained by gene expression profiling was able to segregate the patients after breast conservation treatment into a high risk versus a low risk of local recurrence at 10 years (29% vs. 5%, respectively; P =.0008) (36). The wound signature profile remained a significant predictor for local recurrence on multivariate analysis (P =.01) Freedman et al., (17) defined three groups: ER or PR (+), HER2, and TN. Patients in the TN and HER2 groups were more likely to have T2 and grade 3 diseases. The median age of the TN and HER2 groups was both 54 years, which was also older than that of the present study. They also reported that there was no overall difference in total locoregional recurrence rates between the three groups (p=0.13). Additionally, a higher rate of distant metastases in the HER2 group was observed (11.9%, p=0.009) which translated into a lower recurrence-free survival rate (84%, p=0.005). It is also notable that, despite the use of adjuvant systemic chemotherapy, triple negative patients seemed to have a poor prognosis, with a distant metastasis-free survival rate of only 52% at 5 years. The interpretation of these findings remains debatable given the relatively small number of patients and the retrospective nature of this study, and further studies evaluating the impact of adjuvant systemic therapy in triple negative patients is warranted. By definition of their lack of receptors for ER, PR, and HER2/ neu, patients with triple negative tumors are not candidates for adjuvant hormonal therapy or trastuzumab (37). Basal-like tumors have been shown to overexpress HER1 (epidermal growth factor), and patients with these tumors may be candidates for prospective studies evaluating targeted antibodies against epidermal growth factor that are already in clinical use (5,38). Clearly, additional prospective and retrospective studies are warranted to further refine prognosis and optimize treatment in patients with triple negative breast cancers. We have demonstrated here, using the simple commonly available markers of ER, PR, and HER2/neu, that patients with triple negative breast cancers have a relatively poor prognosis, with a poorer distant metastasis-free, disease-free, and Overall survival. The current study has several potential limitations. Firstly, because HER2 testing has evolved over time, there was not uniform testing for all of the breast carcinomas in the current study. Second, the relatively small number of patients in the triple-negative subset limited the power to detect small, but potentially statistically significant, differences. Whether alternative forms of chemotherapy for these breast cancer patients, with or without biologic modifiers, will prove superior can only be addressed by well-designed prospective studies. Third, the groups were differentiated based on tumor markers, not gene profiling. Nonetheless, segregating patients into prognostic groups on the basis of tumor markers is clinically relevant, particularly in view of targeted therapies currently available. Another potential weakness of the study is unavoidable selection biases in a retrospective series such as this. For the current study, only patients who had available ER, PR, and HER2/neu data were included. Finally, the patients were treated largely before the routine use of trastuzumab and lapatinib. Thus, the results in the current study, particularly for the HER2-positive patients, could be substantially different for patients treated using newer targeted therapies. Conclusion Although women with triple-negative tumors had a higher rate of local failure and a lower rate of freedom from distant metastases compared with women without triple-negative tumors, the absolute difference was relatively small and not statistically significant and therefore does not preclude breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Correspondence author Omnia Abd el-fattah Clinical Oncology Department, Faculty of Medicine, Tanta University omniaabdelfattah@yahoo.com 5. References 1. Jae Myoung Noh, Doo Ho Choi, Seung Jae Huh, Won Park et al. (2011): Patterns of Recurrence after Breast-Conserving 2. Sørlie T. (2004): Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer;40: Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. (2001): Gene expression patterns of breast carcinomas distinguish tumor 180
7 subclasses with clinical implications. Proc Natl Acad Sci U S A;98: Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23: Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. (2003): Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A;100: Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. (2003): Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A; 100: Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. (2006): Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA;295: Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. (2000); Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10: Rakha EA, Reis-Filho JS, Ellis IO. (2008): Basallike breast cancer: a critical review. J Clin Oncol;26: van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Longterm results of a randomized trial comparing breastconserving therapy with mastectomy: European Organization for Research and Treatment of Cancer trial. J Natl Cancer Inst 2000;92: Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. (2002):Twenty-year follow-up of a randomized study comparing breastconserving surgery with radical mastectomy for early breast cancer. N Engl J Med;347: Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al.(2003): Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer; 98: Lazovich D, Solomon CC, Thomas DB, Moe RE, White E. (1999): Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer;86: Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. (2006): Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol;24: Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. (2008): Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breastconserving therapy. J Clin Oncol;26: Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. (2007): Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res.;13(15 Pt 1): Freedman GM, Anderson PR, Li T, Nicolaou N. (2009): Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer;115: Greene FL, Page DL, Fleming ID, et al. (2002): eds. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; Kaplan EL, Meier P. (1958): Nonparametric estimation from incomplete observations. J Am Stat Assoc; 53: Mantel N. (1966): Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep; 50: Cox DR. (1972): Regression models and life tables. J Roy Statist Soc Ser B; 34: Perou CM, Sørlie T, Eisen MB, et al. (2000): Molecular portraits of human breast tumours. Nature 406: , 23-Foulkes WD, Smith IE, Reis-Filho JS(2010): Triple-negative breast cancer. N Engl J Med., 363: , 24-Brenton JD, Carey LA, Ahmed AA, et al. (2005): Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 23: , 25- Collett K, Stefansson IM, Eide J, et al. (2005): A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14: , 26. Bartelink H, Horiot JC, Poortmans P, et al. (2001): Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med., 345: , 27. de la Rochefordiere A, Asselain B, Campana F, et al. (1993): Age as prognostic factor in premenopausal breast carcinoma. Lancet, 341: Fowble BL, Schultz DJ, Overmoyer B, et al. (1994): The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys., 30:23-33, 29. Harrold EV, Turner BC, Matloff ET, et al. (1998): Local recurrence in the conservatively 181
8 treated breast cancer patient: A correlation with age and family history. Cancer J Sci Am 4: , 30. Recht A, Connolly JL, Schnitt SJ, et al. (1988): The effect of young age on tumor recurrence in the treated breast after conservativesurgery and radiotherapy.int J Radiat Oncol Biol Phys 14:3-10, 31. Vicini FA, Recht (2002 A): Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: A critical review of the literature. J Clin Oncol., 20: , 32-Harris EE, Hwang WT, Lee EA, et al. (2006): The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. Breast J; 12: Parikh RR, Yang Q, Higgins SA, et al. (2008): Outcomes in young women with breastcancer of triple-negative phenotype: the prognostic significance of CK19 expression.int J Radiat Oncol Biol Phys; 70: Cheang MC, Voduc D, Tyldesley S, et al. (2008): Breast cancer molecular subtypes and locoregional recurrence. J Clin Oncol; 26(15 suppl):9s (Abstract 510). 35-Mamounas E, Tang G, Bryant J, et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in nodenegative ER-positive. breast cancer: results from the NSABP B-14 and NSABP B-20. Proceedings of the San Antonio Breast Cancer Symposium; December 8-11, Abstract Nuyten DS, Kreike B, Hart AA, et al. (2006): Predicting a local recurrence after breast conserving therapy by gene expression profiling. Breast Cancer Res; 8:R Romond EH, Perez EA, Bryant J, et al. (2005): Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med., 353: ,. 38-Matos I, Dufloth R, Alvarenga M, et al. (2005): P63, cytokeratin 5, and P-cadherin: Three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447: /6/
J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationClinical pathological and epidemiological study of triple negative breast cancer
International Journal of Research in Medical Sciences Ajay A et al. Int J Res Med Sci. 217 Jun;5(6):2657-2661 www.msjonline.org pissn 232-71 eissn 232-12 Original Research Article DOI: http://dx.doi.org/1.1823/232-12.ijrms2172465
More informationBreast-Conserving Therapy for Triple-Negative Breast Cancer
Research Original Investigation PACIFIC COAST SURGICAL ASSOCIATION Breast-Conserving Therapy for Triple-Negative Breast Cancer Alexandra Gangi, MD; Alice Chung, MD; James Mirocha, MS; Douglas Z. Liou,
More informationEGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
ONCOLOGY REPORTS 21: 413-417, 2009 413 EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer HIROKO NOGI 1, TADASHI KOBAYASHI 2, MASAFUMI SUZUKI 3, ISAO TABEI
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationThe Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
More informationComparison of survival outcomes between modified radical mastectomy and breast conserving surgery in early breast cancer patients
http://dx.doi.org/10.7180/kmj.2016.31.1.19 KMJ Original Article Comparison of survival outcomes between modified radical mastectomy and breast conserving surgery in early breast cancer patients Yoon Seok
More informationTreatment results and predictors of local recurrences after breast conserving therapy in early breast carcinoma
Journal of BUON 8: 241-246, 2003 2003 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Treatment results and predictors of local recurrences after breast conserving therapy in early breast
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationThe Role of a Boost Radiation Dose in Patients with Negative Re-Excision Findings
24 The Open Breast Cancer Journal, 2011, 3, 24-28 Open Access The Role of a Boost Radiation Dose in with Negative Re-Excision Melanie C. Smitt and Kathleen C. Horst * Department of Radiation Oncology,
More informationBreast Cancer Subtypes and the Risk of Local and Regional Relapse
VOLUME 28 NUMBER 10 APRIL 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Breast Cancer s and the Risk of Local and Regional Relapse K. David Voduc, Maggie C.U. Cheang, Scott Tyldesley,
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationEditorial Process: Submission:11/30/2017 Acceptance:01/04/2019
RESEARCH ARTICLE Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 in Non-Metastatic Triple-Negative Breast Cancer O Al jarroudi*, A Zaimi, S A Brahmi, S Afqir Abstract Introduction: Triple-negative
More informationRESEARCH ARTICLE. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India
APJCP.2016.17.6.2995 RESEARCH ARTICLE Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India Dinesh Chandra Doval 1,2 *, P Suresh 1, Rupal Sinha 2, Saud Azam 2, Ullas Batra
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 2015 June; 18(2): 143-148 Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry Malcolm D. Mattes, Jay K.
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationOncologic safety of breast-conserving surgery in breast cancer patients under the age of 35
Korean Journal of Clinical Oncology 217;13:32-38 https://doi.org/1.14216/kjco.174 pissn 1738-882 eissn 2288-484 Original Article Oncologic safety of breast-conserving surgery in breast cancer patients
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationYoung Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 217;49(2):484-493 Original Article https://doi.org/1.4143/crt.216.246 Open Access Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive
More informationSCIENCE CHINA Life Sciences
SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationLocoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype
Breast Cancer Res Treat (2012) 133:831 841 DOI 10.1007/s10549-011-1891-6 REVIEW Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype Aoife J. Lowery Malcolm R.
More informationWhat to do after pcr in different subtypes?
What to do after pcr in different subtypes? Luca Moscetti Breast Unit Università degli Studi di Modena e Reggio Emilia Policlinico di Modena, Italy Aims of neoadjuvant therapy in breast cancer Primary
More informationHormone receptor sensitivity in Breast Cancer patients in Pune city of Maharashtra State, India A retrospective study
International Journal of Advanced Biotechnology and Research(IJBR) ISSN 0976-2612, Online ISSN 2278 599X, Vol 6, Issue2, 2015, pp196-202 http://www.bipublication.com Research Article Hormone sensitivity
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationBreast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
DOI 10.1007/s00268-015-3133-2 ORIGINAL SCIENTIFIC REPORT Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationClinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer
Original Articles Jpn J Clin Oncol 2012;42(6)471 476 doi:10.1093/jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li,
More informationTreatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy
Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy Kyoung Ju Kim 1, Seung Jae Huh 1, Jung-Hyun Yang 2, Won Park 1, Seok Jin Nam
More informationReal-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive lymph nodes: a retrospective study
Journal of Radiation Research, 2014, 55, 121 128 doi: 10.1093/jrr/rrt084 Advance Access Publication 20 June 2013 Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationTime to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study
Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective
More informationResponse to Paclitaxel in Node-positive Triple Negative Breast Cancer
J Korean Surg Soc 2010;79:173-179 DOI: 10.4174/jkss.2010.79.3.173 원 저 Response to Paclitaxel in Node-positive Triple Negative Breast Cancer Department of Surgery, Kosin University College of Medicine,
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationUnexpected features of breast cancer subtype
Liu et al. World Journal of Surgical Oncology (2015) 13:249 DOI 10.1186/s12957-015-0665-8 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Unexpected features of breast cancer subtype Ye-huan Liu,
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationConcordance among Gene-Expression Based Predictors for Breast Cancer
The new england journal of medicine original article Concordance among Gene-Expression Based Predictors for Breast Cancer Cheng Fan, M.S., Daniel S. Oh, Ph.D., Lodewyk Wessels, Ph.D., Britta Weigelt, Ph.D.,
More informationMETASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER
Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationGenomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationJournal of Breast Cancer
Journal of Breast Cancer ORIGINAL ARTICLE J Breast Cancer 2011 March; 14(1): 14-19 αb-crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer Hae Sung Kim, Younok Lee, Young Ah
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationComparison of Triple Negative Breast Cancer between Asian and Western Data Sets
2010 IEEE International Conference on Bioinformatics and Biomedicine Workshops Comparison of Triple Negative Breast Cancer between Asian and Western Data Sets Lee H. Chen Bioinformatics and Biostatistics
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationResidual cancer burden in locally advanced breast cancer: a superior tool
ABSTRACT Objectives Locally advanced breast cancer (LABC) poses a difficult clinical challenge with an overall poor long-term prognosis. The strength of the association between tumour characteristics,
More informationClassifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology
2059 Classifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology New Primary Tumors Have More Favorable Outcomes than True Local Disease Recurrences Eugene Huang,
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationCirculating Tumor Cells in non- Metastatic Triple Negative Breast Cancer
Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer Carolyn Hall, Ph.D. Department of Surgical Oncology The University of Texas MD Anderson Cancer Center Triple Negative Breast Cancer
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationPresent Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy
Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is
More informationCHARLES M. PEROU. The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
The Oncologist Molecular Stratification of Triple-Negative Breast Cancers CHARLES M. PEROU The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Key Words. Triple-negative breast
More informationRepeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates
Ann Surg Oncol (2012) 19:3771 3776 DOI 10.1245/s10434-012-2404-5 ORIGINAL ARTICLE BREAST ONCOLOGY Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationPrognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, G.
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationNo association between triple negative breast cancer and prognosis of patients receiving breast conserving treatment
7862 No association between triple negative breast cancer and prognosis of patients receiving breast conserving treatment LAN MU 1 3*, YUXIANG LIU 4*, MENG XIAO 1 3, WEISE LIU 1 3, MIAO LIU 1 3 and XIN
More informationBreast cancer classification: beyond the intrinsic molecular subtypes
Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationResection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland
Resection Margins in Breast Conserving Surgery Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland Breast Conserving Surgery 1 Probably one of the most important innovation in cancer surgery
More informationDifferences in outcome for positive margins in a large cohort of breast cancer patients treated with breast-conserving therapy
Acta Oncologica ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: http://www.tandfonline.com/loi/ionc20 Differences in outcome for positive margins in a large cohort of breast cancer patients
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationAre there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)?
Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)? Department of General Surgery, Anam Hospital, Korea University, College of Medicine, 126-, Anam-dong
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.3.1187 Molecular Subtype of Breast Cancer, MVD and VEGF Expression RESEARCH ARTICLE Clinicopathologic Features of Breast Carcinomas Classified by Biomarkers
More informationAnalysis of loco-regional and distant recurrences in breast cancer after conservative surgery
Elsayed et al. World Journal of Surgical Oncology (2016) 14:144 DOI 10.1186/s12957-016-0881-x RESEARCH Analysis of loco-regional and distant recurrences in breast cancer after conservative surgery Mostafa
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationSurvival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast
10.14456/apjcp.2016.191/APJCP.2016.17.8.3911 Survival of Triple Negative and Triple Positive Breast Cancers RESEARCH ARTICLE Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison
More informationModern classification of breast cancer-should we stick with morphology or convert to molecular profiles?
Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles? Ian Ellis Professor of Cancer Pathology Molecular Medical Sciences University of Nottingham Dept
More informationCLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS
CLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS S. Chahbouni¹, A. Amarti 2, N. Hammas 3, L. Chbani 3, H. El fatemi 3 1 Department
More information2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features
2017 Topics Biology of Breast Cancer Early-stage HER2+ breast cancer-can we avoid RT? Prediction tools for locoregional recurrence Omission of RT in older women with low-risk features Local-Regional Recurrence
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationHow to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
Global Breast Cancer Conference 2016 & 5 th International Breast Cancer Symposium April 29 th 2016, 09:40-10:50 How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
More informationThe Expression of Basal Cytokeratins in Breast Cancers
Global Journal of Medical Research: C Microbiology and Pathology Volume 17 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online
More informationARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More information